Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and marketing of innovative therapies for gastrointestinal and liver diseases. Founded in 1960, the company has established a strong presence across Europe and beyond, focusing on areas such as inflammatory bowel disease and hepatology. With a commitment to research and development, Dr. Falk Pharma offers a range of unique products and services that address unmet medical needs. Their portfolio includes prescription medications and specialised nutritional products, distinguished by their efficacy and safety profiles. Recognised for its dedication to patient care, Dr. Falk Pharma has achieved significant milestones, solidifying its position as a trusted partner in the healthcare community.
DitchCarbon Score
How does Dr. Falk Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr. Falk Pharma GmbH's score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dr. Falk Pharma GmbH's reported carbon emissions
Dr. Falk Pharma GmbH, headquartered in Germany, currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting its emissions. In the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are often encouraged to set measurable targets for reducing greenhouse gas emissions across all scopes. As the industry evolves, it is likely that Dr. Falk Pharma will develop and disclose its climate strategies and emissions data in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dr. Falk Pharma GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
